Who are Baclofen IR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Propofol-Lipuro, Pregabalin, Oxaliplatin, placebo and pregabalin, propofol (drug).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/baclofen-ir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Baclofen IR — Competitive Intelligence Brief

Baclofen IR (Baclofen IR) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GABA receptor agonist. Area: Neurology.

phase 2 GABA receptor agonist GABA_B receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Baclofen IR (Baclofen IR) — Impax Laboratories, LLC. Baclofen IR is a central nervous system depressant that acts as a GABA_B receptor agonist.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Baclofen IR TARGET	Baclofen IR	Impax Laboratories, LLC	phase 2	GABA receptor agonist	GABA_B receptor
Propofol-Lipuro	Propofol-Lipuro	University Hospital, Grenoble	phase 3	GABA receptor agonist	GABA_A receptor
Pregabalin, Oxaliplatin	Pregabalin, Oxaliplatin	University of Sao Paulo	phase 3	GABA receptor agonist, platinum-based DNA crosslinking agent	GABA receptor, DNA
placebo and pregabalin	placebo and pregabalin	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	phase 3	GABA receptor agonist	alpha2-delta subunit of voltage-gated calcium channels
propofol (drug)	propofol (drug)	B. Braun Melsungen AG	phase 3	GABA receptor agonist	GABA_A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GABA receptor agonist class)

Amsterdam UMC, location VUmc · 1 drug in this class
B. Braun Melsungen AG · 1 drug in this class
Impax Laboratories, LLC · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
University Hospital, Grenoble · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Baclofen IR — Competitive Intelligence Brief. https://druglandscape.com/ci/baclofen-ir. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab